Department of Biochemical and Pharmaceutical Engineering, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran; Aachen-Maastricht Institute for Biobased Materials, Faculty of Science and Engineering, Maastricht University, The Netherlands.
Department of Biochemical and Pharmaceutical Engineering, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Int J Pharm. 2023 Oct 15;645:123366. doi: 10.1016/j.ijpharm.2023.123366. Epub 2023 Sep 3.
The pH-responsive drug release approach in combination with three-dimensional (3D) printing for colon-specific oral drug administration can address the limitations of current treatments such as orally administered solid tablets. Such existing treatments fail to effectively deliver the right drug dosage to the colon. In order to achieve targeted drug release profiles, this work aimed at designing and producing 3D printed tablet shells using Eudragit® FS100 and polylactic acid (PLA) where the core was filled with 100 µl of N-acetylglucosamine (GlcNAc)-loaded methyl cellulose (MC) hydrogel. To meet the requirements of such tablets, the effects of polymer blending ratios and MC concentrations on physical, thermal, and material properties of various components of the tablets and most importantly in vitro drug release kinetics were investigated. The tablets with 80/20 wt% of Eudragit® FS100/PLA and the drug-loaded hydrogel with 30 mg/ml GlcNAc and 3% w/v MC showed the most promising results having the best printability, processability, and drug release kinetics besides being non-cytotoxic. Manufacturing of these tablets will be the first milestone in shifting from the conventional "one size fits all" approach to personalized medicine where different dosages and various combinations of drugs can be effectively delivered to the inflammation site.
pH 响应型药物释放方法与三维（3D）打印相结合，用于结肠特异性口服给药，可以解决当前治疗方法的局限性，例如口服固体制剂。这些现有的治疗方法无法将正确的药物剂量有效递送到结肠。为了实现靶向药物释放特性，本工作旨在设计和生产使用 Eudragit® FS100 和聚乳酸（PLA）的 3D 打印片剂外壳，其中核心填充有 100µl 负载 N-乙酰葡萄糖胺（GlcNAc）的甲基纤维素（MC）水凝胶。为了满足这些片剂的要求，研究了聚合物混合比和 MC 浓度对片剂各组成部分的物理、热和材料性能的影响，以及最重要的是体外药物释放动力学的影响。在 80/20wt% Eudragit® FS100/PLA 和载药水凝胶中，GlcNAc 为 30mg/ml 和 MC 为 3%w/v 的片剂具有最佳的打印性能、可加工性和药物释放动力学，并且无细胞毒性。这些片剂的制造将是从传统的“一刀切”方法向个性化药物转变的第一步，其中可以有效地将不同剂量和各种药物组合递送到炎症部位。
